Add thelocalreport.in As A Trusted Source
Food and Drug Administration A new pill has been approved to treat hot flashes and night sweats for menopausal women.
menopause It occurs when a woman’s ovaries stop producing reproductive hormones, usually in her early 50s. However, it has many uncomfortable side effects, but the most common are hot flashes and night sweats. National Menopause FoundationUp to 80 percent of menopausal women experience hot flashes and night sweats, the new York Times Report.
Drugmaker Bayer created the first FDA-approved non-hormonal drug to combat hot flashes and night sweats that blocks two types of brain receptors that affect temperature regulation.
The drug, called alizenetant, sold under the brand name Linquet, was approved by the FDA on Friday to treat moderate to severe vasomotor symptoms, commonly known as hot flashes and night sweats.
“The FDA approval of Linquet represents an important new option for women and providers treating moderate to severe hot flashes due to menopause,” said Dr. Yasmin Vahdan, head of medical affairs for Bayer in the US and North America. Said In a statement.
“As a global leader in women’s health care with over 100 years of research and experience, we are proud to bring this new treatment option to market for women who are going through menopause and are looking for hot flash relief.”
This medicine was approved in the United Kingdom by the Medicines and Healthcare products Regulatory Agency in July, becoming the world’s first regulator to do so. Now it has also been approved in Australia, Canada and Switzerland.
The FDA’s approval comes after three Phase III clinical trials, which test the safety and how well a new drug works. Trials showed that Linquat significantly reduced the frequency and severity of hot flashes and night sweats. This medicine can also help with sleep problems.
Common side effects include headache, fatigue, and stomach pain.
Linquet, along with other non-hormonal menopause symptom treatments, offers an option for women who either cannot or are uncomfortable using hormone therapy.
Bayer said the drug is expected to be available in the US by November. According to the company, the drug costs $625 for a 30-day supply, but some patients may have to pay as little as $25.